Double maintains 1 strategies that include SAVA - Cassava Sciences, Inc.
Current Value
$2.081 Year Return
Current Value
$2.081 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FDMT | 21.21% | $148.24M | -87.52% | 0.00% |
MLI | 20.79% | $8.75B | +35.66% | 1.07% |
ITOS | 19.86% | $305.04M | -55.47% | 0.00% |
PBT | 19.42% | $497.32M | -17.48% | 3.88% |
NKE | 19.35% | $92.10B | -32.00% | 2.46% |
DNLI | 19.35% | $2.06B | -30.04% | 0.00% |
AVXL | 19.29% | $714.56M | +86.00% | 0.00% |
MOD | 18.86% | $5.39B | -1.27% | 0.00% |
CMRE | 18.76% | $1.05B | -18.47% | 5.23% |
DASH | 18.69% | $83.52B | +69.68% | 0.00% |
BCRX | 18.40% | $2.14B | +57.81% | 0.00% |
WBX | 18.40% | $83.76M | -80.79% | 0.00% |
NXE | 18.35% | $3.20B | -26.15% | 0.00% |
BX | 18.18% | $178.04B | +14.76% | 2.38% |
POWL | 18.15% | $2.15B | +8.63% | 0.44% |
RMBL | 18.03% | $90.48M | -63.51% | 0.00% |
CRBU | 17.93% | $78.11M | -76.60% | 0.00% |
VST | 17.79% | $51.60B | +63.26% | 0.57% |
WBTN | 17.71% | $1.16B | -57.71% | 0.00% |
STRL | 17.65% | $5.62B | +42.14% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTC | -13.95% | $4.48B | 0.15% |
BILZ | -13.30% | $876.85M | 0.14% |
USFR | -10.56% | $18.91B | 0.15% |
PULS | -9.74% | $11.17B | 0.15% |
IBTG | -9.60% | $1.88B | 0.07% |
NEAR | -9.08% | $3.26B | 0.25% |
VRIG | -8.80% | $1.19B | 0.3% |
SPTS | -8.76% | $5.76B | 0.03% |
GOVT | -8.65% | $27.25B | 0.05% |
BTAL | -8.45% | $361.41M | 1.43% |
TFLO | -7.41% | $7.06B | 0.15% |
IGOV | -7.17% | $994.85M | 0.35% |
IBTM | -6.97% | $313.33M | 0.07% |
USTB | -6.96% | $1.19B | 0.35% |
UTWO | -6.95% | $387.71M | 0.15% |
IBTI | -6.90% | $995.39M | 0.07% |
FLDR | -6.77% | $841.44M | 0.15% |
AGZ | -6.75% | $607.46M | 0.2% |
OWNS | -6.67% | $134.57M | 0.3% |
JMST | -6.64% | $3.65B | 0.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XPH | 24.18% | $136.58M | 0.35% |
NUKZ | 18.21% | $218.87M | 0.85% |
URA | 17.94% | $2.88B | 0.69% |
PTH | 17.64% | $96.56M | 0.6% |
URNM | 17.17% | $1.44B | 0.75% |
AMDY | 15.98% | $140.44M | 1.23% |
URNJ | 15.82% | $246.59M | 0.8% |
HODL | 15.58% | $1.54B | 0.25% |
BTCW | 15.52% | $161.85M | 0.3% |
EZBC | 15.52% | $533.04M | 0.29% |
BTCO | 15.42% | $564.39M | 0.39% |
TESL | 15.38% | $30.66M | 1.2% |
DEFI | 15.30% | $13.07M | 0.94% |
BITB | 15.28% | $4.00B | 0.2% |
FBTC | 15.25% | $20.76B | 0.25% |
BRRR | 15.23% | $637.29M | 0.25% |
BITO | 15.20% | $2.49B | 0.95% |
ARKB | 15.20% | $5.06B | 0.21% |
IBIT | 15.16% | $65.44B | 0.25% |
GBTC | 15.13% | $19.74B | 1.5% |
Yahoo
As the U.S. stock market holds steady, with the S&P 500 extending its winning streak and investor sentiment buoyed by easing trade tensions between the U.S. and China, attention has turned to various investment opportunities. Though "penny stock" might sound like a relic of past trading days, it still highlights smaller or less-established companies that can offer great value. By focusing on those with robust financials and clear growth trajectories, investors may find diamonds in the rough...
Yahoo
License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today reported financial results for the first quarter e
Finnhub
Cassava Sciences, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 23.4 million compared to net income of USD...
Finnhub
AUSTIN, Texas - Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, announced that Angelique...
Yahoo
As SVP, Neuroscience, Dr. Bordey will lead Cassava’s ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that
Yahoo
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Medical Officer, effective May 9, 2025. The Company also appointed Jack Moore, PhD, as Senior Vice Presid
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OPI | -23.82% | $16.91M | -89.63% | 16.66% |
SEG | -22.17% | $239.93M | -26.61% | 0.00% |
JWN | -17.18% | $4.10B | +15.75% | 3.10% |
IRTC | -16.71% | $4.50B | +42.90% | 0.00% |
CNP | -15.91% | $24.30B | +24.35% | 2.82% |
BBWI | -15.75% | $7.24B | -30.60% | 2.34% |
QUAD | -15.25% | $290.01M | +15.76% | 3.91% |
VZ | -14.29% | $183.32B | +8.02% | 6.21% |
KODK | -14.27% | $526.01M | +28.91% | 0.00% |
GLNG | -14.00% | $4.08B | +44.84% | 2.55% |
AGL | -13.36% | $1.06B | -54.30% | 0.00% |
VUZI | -12.82% | $200.52M | +75.33% | 0.00% |
FIZZ | -12.64% | $4.16B | +0.40% | 0.00% |
BARK | -12.56% | $220.39M | +1.61% | 0.00% |
STRA | -12.31% | $2.14B | -25.99% | 2.71% |
CME | -12.02% | $98.74B | +28.80% | 3.84% |
HRL | -11.96% | $16.59B | -16.43% | 3.81% |
TBRG | -11.58% | $368.07M | +164.86% | 0.00% |
QNTM | -11.45% | $21.04M | -55.31% | 0.00% |
VITL | -11.10% | $1.53B | -9.44% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BSMR | <0.01% | $245.57M | 0.18% |
IBDY | -0.02% | $718.22M | 0.1% |
MUB | 0.02% | $38.67B | 0.05% |
ENZL | -0.04% | $75.59M | 0.5% |
UBND | 0.06% | $727.50M | 0.4% |
EDIV | 0.07% | $710.93M | 0.49% |
MSOS | -0.07% | $354.62M | 0.77% |
SRET | -0.09% | $180.31M | 0.59% |
PZA | 0.10% | $2.89B | 0.28% |
CNBS | 0.10% | $69.42M | 0.77% |
YEAR | 0.11% | $1.40B | 0.25% |
DFNM | -0.12% | $1.53B | 0.17% |
BUXX | -0.12% | $284.43M | 0.25% |
TFI | -0.13% | $3.15B | 0.23% |
FMB | -0.14% | $1.91B | 0.65% |
PFLD | 0.14% | $498.33M | 0.45% |
MUNI | 0.17% | $1.99B | 0.35% |
SUB | 0.17% | $9.40B | 0.07% |
IXJ | 0.19% | $3.78B | 0.41% |
WIP | -0.19% | $343.20M | 0.5% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
INCY | -<0.01% | $12.15B | +10.38% | 0.00% |
MTH | -<0.01% | $4.86B | -26.02% | 3.94% |
YORW | -0.01% | $469.88M | -15.42% | 2.64% |
FLGT | -0.01% | $610.09M | -10.93% | 0.00% |
MYRG | -0.01% | $2.54B | +7.70% | 0.00% |
DNUT | -0.01% | $548.27M | -73.07% | 4.37% |
FCPT | -0.01% | $2.75B | +9.40% | 5.12% |
LNW | -0.01% | $7.05B | -11.86% | 0.00% |
IRDM | 0.02% | $2.77B | -15.74% | 2.18% |
RNG | -0.02% | $2.52B | -23.43% | 0.00% |
CRWD | 0.02% | $107.56B | +27.36% | 0.00% |
OPRT | 0.02% | $259.51M | +84.04% | 0.00% |
KVYO | 0.02% | $9.63B | +43.09% | 0.00% |
NI | 0.02% | $18.21B | +32.73% | 2.81% |
KVUE | -0.03% | $45.85B | +15.92% | 3.41% |
UBER | 0.03% | $188.54B | +36.50% | 0.00% |
KSPI | -0.03% | $15.59B | -31.07% | 2.14% |
ALXO | -0.03% | $23.29M | -97.03% | 0.00% |
SHAK | -0.03% | $4.71B | +15.41% | 0.00% |
REFI | -0.04% | $313.46M | -3.01% | 13.79% |